During the past decade, Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy conducted 80 clinical trials. In the 10-year time frame, 80 clinical trials started and 49 clinical trials were completed, i.e. on average, 61.3% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 32 clinical trials were completed. i.e. 78% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" #1 sponsor was "Janssen Research & Development, LLC" with 17 trials, followed by "Pfizer" with 10 trials sponsored, "Eli Lilly and Company" with 8 trials sponsored, "Boehringer Ingelheim" with 7 trials sponsored and "Celgene" with 7 trials sponsored. Other sponsors include 50 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" #1 collaborator was "OCT Clinical Trials" with 3 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" are "Rheumatoid Arthritis" (13 trials), "Arthritis, Rheumatoid" (8 trials), "Crohn's Disease" (7 trials), "Ulcerative Colitis" (7 trials) and "Arthritis, Psoriatic" (6 trials). Many other conditions were trialed in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" in a lesser frequency.

Most popular intervention types in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" are "Drug" (91 trials), "Other" (13 trials), "Biological" (10 trials), "Device" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Guselkumab" (8 trials), "Mirikizumab" (4 trials), "Nipocalimab" (4 trials) and "Ontamalimab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy" are 99 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 38 active trials in "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy". 1 are not yet recruiting, 20 are recruiting, 16 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 47 completed trials in Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy, 5 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 55 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".

Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy has several departments that took part in Clinical trials: "Szpital Uniwersytecki; nr 2 im. Dr J. Biziela; Klinika Reumatologii i Ukladowych Chorob" - 7 trials, "Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii" - 3 trials, "The Chair of Medical Biology, Collegium Medicum of Nicolaus Copernicus University" - 2 trials, "Szpital Uniwersytecki nr 2 im. dr Jana Biziela w BydgoszczyKlinika Hematologii" - 2 trials